Aldosterone breakthrough is a clinical phenomenon that occurs upon treatment with the renin–angiotensin system (RAS) inhibitors angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists [75], and this phenomenon attenuates the organ-protective effects of RAS inhibitors against DN through the actions of mineralocorticoid receptors [76]. Here, ACE is linked to liver dysplastic nodule.